Joseph J. Buggy
Cognition, Santé, Société · 140 works · 17,558 citations · h-index 46
Top works
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
- A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
- Cloning and characterization of a novel human histone deacetylase, HDAC8
- Identification of Substrates of Human Protein-tyrosine Phosphatase PTPN22
- Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
- Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)